FDA approves Roivant's LISRAYA for dermatomyositis, launch begins immediatelyAug 28Regulatory decisionbrepocitinibRoivant Sciences Ltd.
Roivant reports Q1 fiscal 2027 results, pipeline on track across four vantsAug 6Quarterly updateRoivant Sciences Ltd.
Sign inSign in